STOCK TITAN
  1. Home
  2. Sec-filings
  3. CLBT
  4. [Form 4] Cellebrite DI Ltd. Insider Trading Activity

Cellebrite advisor sells 25,299 shares at $11.29

Filing Impact
(Moderate)
Filing Sentiment
(Negative)
Form Type
4

Rhea-AI Filing Summary

Cellebrite DI Ltd. (CLBT) reported that advisor Thomas E. Hogan sold ordinary shares in a Form 4 filing. On August 25, 2026, he sold 25,299 ordinary shares at a weighted average price of $11.2934 per share in open-market or private transactions, at prices ranging from $11.205 to $11.36. The filing states these shares had been granted as restricted stock units (RSUs) on February 10, 2026 and that the disposition was associated with the reporting person’s tax obligations arising from RSU vesting. Following the sale, Hogan directly held 765,249 ordinary shares of Cellebrite.

Positive

  • None.

Negative

  • None.
Insider Hogan Thomas E.
Role Insider
Sold 25,299 shs ($286K)
Type Security Shares Price Value
Sale Ordinary shares, par value NIS 0.00001 F1, F2 25,299 $11.2934 $286K
Holdings After Transaction: Ordinary shares, par value NIS 0.00001 — 765,249 shares (Direct)
Footnotes (2)
  1. F1. The shares reported as disposed herein were granted on February 10, 2026 , in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs.
  2. F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.205 to $11.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Shares sold 25,299 shares Ordinary shares sold on August 25, 2026
Weighted average sale price $11.2934 per share Weighted average for transactions on August 25, 2026
Sale price range $11.205 to $11.36 per share Range of prices for multiple sale transactions
Shares owned after transaction 765,249 shares Direct holdings of Thomas E. Hogan following the sale
RSU grant date February 10, 2026 Date shares were granted as restricted stock units (RSUs)
restricted stock units ("RSUs") financial
"were granted on February 10, 2026 , in the form of restricted stock units ("RSUs")."
Restricted stock units (RSUs) are a company promise to give an employee shares of stock (or cash equivalent) in the future, but only after certain conditions—usually staying with the company for a set time or hitting performance goals—are met. Investors watch RSUs because when they vest they increase the number of shares outstanding and can lead insiders to sell shares, affecting share price, company dilution and the true cost of employee pay.
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
tax obligations financial
"The disposition of shares is associated with tax obligations of the reporting person"

FAQ

What insider transaction did CLBT advisor Thomas E. Hogan report?
Thomas E. Hogan reported a sale of 25,299 ordinary shares of Cellebrite DI Ltd. on August 25, 2026. The transaction was a sale in open-market or private transactions, reported on a Form 4 filed with the SEC.

At what price were the CLBT shares sold in Hogan’s Form 4?
The shares were sold at a weighted average price of $11.2934 per share. The filing states they were sold in multiple transactions at prices ranging from $11.205 to $11.36, inclusive.

How many CLBT shares does Thomas E. Hogan hold after this transaction?
After the reported sale, Thomas E. Hogan directly holds 765,249 ordinary shares of Cellebrite DI Ltd., according to the Form 4.

Why did Thomas E. Hogan dispose of CLBT shares according to the filing?
The filing states that the disposed shares were granted as restricted stock units (RSUs) on February 10, 2026 and that the disposition is associated with Hogan’s tax obligations related to the vesting of those RSUs.

Was Hogan’s CLBT share sale under a Rule 10b5-1 trading plan?
The Form 4 indicates the Rule 10b5-1 checkbox is not marked as affirming a trading plan. The footnotes do not describe the sale as being made pursuant to a Rule 10b5-1 plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
X
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Hogan Thomas E.
(Last)(First)(Middle)
94 SHLOMO SHMELZER ROAD
(Street)
PETAH TIKVA4970602
(City)(State)(Zip)
ISRAEL
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cellebrite DI Ltd. [ CLBT ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
Officer (give title below)XOther (specify below)
Advisor
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
08/25/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary shares, par value NIS 0.0000108/25/2026S(1)25,299D$11.2934(2)765,249D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. The shares reported as disposed herein were granted on February 10, 2026 , in the form of restricted stock units ("RSUs"). The disposition of shares is associated with tax obligations of the reporting person associated with the vesting of the RSUs.
2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.205 to $11.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Remarks:
/s/ Thomas E. Hogan08/27/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR